Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 3
1950 2
1951 3
1953 2
1956 5
1957 2
1958 4
1959 1
1960 5
1961 2
1962 17
1963 10
1964 11
1965 7
1966 8
1967 8
1968 9
1969 5
1970 1
1971 3
1972 9
1973 4
1974 4
1975 8
1976 4
1977 5
1978 8
1979 11
1980 14
1981 9
1982 18
1983 27
1984 21
1985 31
1986 18
1987 32
1988 53
1989 45
1990 51
1991 53
1992 85
1993 83
1994 91
1995 110
1996 115
1997 95
1998 103
1999 105
2000 141
2001 173
2002 171
2003 201
2004 300
2005 361
2006 396
2007 472
2008 561
2009 666
2010 848
2011 930
2012 1123
2013 1335
2014 1564
2015 1895
2016 2006
2017 2260
2018 2555
2019 3029
2020 3586
2021 3854
2022 4670
2023 4787
2024 5413
2025 6523
2026 4772
2027 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50,128 results

Results by year

Filters applied: . Clear all
Page 1
Report Supervision.
Bassi PRAS, Li W, Wasserthal J, Chen J, Zhou X, Zhu Z, Zhuang C, Decherchi S, Cavalli A, Wang K, Yang Y, Yuille A, Zhou Z. Bassi PRAS, et al. Among authors: wang k. Med Image Anal. 2026 Nov;114:104257. doi: 10.1016/j.media.2026.104257. Epub 2026 Aug 20. Med Image Anal. 2026. PMID: 42664661
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.
Yu J, Xiong A, Wang Q, Chen J, Niu H, Zhou C, Tian P, Zhuang W, Li J, Wang J, Lu J, Gu K, Shi J, Guo J, Di Y, Lv D, Sun D, Cao L, Yang Z, Wu J, Miao L, Pan Y, Li C, Wu X, Yin J, Wang X, Sun M, He M, Cang S, Fang H, Chen P, Zhang M, Yang X, Zhao H, Feng J, Ma X, Hu S, Lu J, Zhao X, Zhuang Z, Sun Y, Sun X, Yu B, Zhu C, Chen J, Xu J, Wang K, Zhou C. Yu J, et al. Among authors: wang k. Signal Transduct Target Ther. 2026 Aug 13;11(1):324. doi: 10.1038/s41392-026-02904-0. Signal Transduct Target Ther. 2026. PMID: 42586967 Free PMC article. Clinical Trial.
Longitudinal alignments and syntheses of multimodal clinical data for personalized medicine with the PULSE framework.
Wu W, Li G, Wang K, Xu H, Xiao H, Hu C, Liu S, Tang C, Liu F, Zou Z, Li B, Li J, Zhang CL, Wong H, Chong I, Lu W, Sun Z, Yin Y, Loupy A, Oermann E, Al Dajani SA, Zhu H, Gootenberg J, Abudayyeh OO, Gladyshev VN, Rasko JEJ, Zhang K; International Consortium of Digital Twins in Healthcare and Medicine. Wu W, et al. Among authors: wang k. Nat Comput Sci. 2026 Aug 26. doi: 10.1038/s43588-026-01026-5. Online ahead of print. Nat Comput Sci. 2026. PMID: 42649447
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
Sun HC, Zhu XD, Shen F, Song TQ, Bai XL, Zeng YY, Chen MS, Huang ZY, Cai JQ, Gao J, Kuang M, Li DY, Xing BC, Li XC, Wen TF, Peng T, Wang YD, Liu LX, Huang C, Shi YH, Huang XW, Wang K, Gao Q, Zhou J, Fan J. Sun HC, et al. Among authors: wang k. Lancet. 2026 Aug 22;408(10556):699-710. doi: 10.1016/S0140-6736(26)01252-3. Lancet. 2026. PMID: 42624156 Clinical Trial.
50,128 results
You have reached the last available page of results. Please see the User Guide for more information.